America’s Social Contract with the Biopharmaceutical Industry

What happens when a drug won’t go generic?

Peter Kolchinsky, Ph.D.

This is the second in a series of articles that aim to define the biopharmaceutical industry’s social contract with America, to examine practices that deviate from that contract, and to propose refinements…

Why wait for generics? In praise of me-too drugs

Peter Kolchinsky, Ph.D

Protecting Off-Patent Sole-source Drugs from Price-Jacking

Peter Kolchinsky, Ph.D.

This is the third in a series of articles that aim to define the biopharmaceutical industry’s social contract with America, to examine practices that deviate from that contract…

The Favors They Do Us: Charging Less in Other Countries Makes Drugs More Affordable in America

False Heroes — How PBMs Add Insult to the Injury of Insurance Cost-Sharing

Direct-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciated

The strange and special case of epinephrine

The biotech social contract stipulates that all drugs must…

Hard Negotiating Tactics: Compulsory Licensing and Willingness to Deny